

# Francesca Romana Ponziani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231409/publications.pdf>

Version: 2024-02-01

101  
papers

4,139  
citations

109321

35  
h-index

128289

60  
g-index

102  
all docs

102  
docs citations

102  
times ranked

5544  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.                                       | 7.3 | 433       |
| 2  | Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , 2009, 51, 682-689.              | 3.7 | 409       |
| 3  | Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. <i>World Journal of Gastroenterology</i> , 2010, 16, 143.   | 3.3 | 248       |
| 4  | Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.       | 2.4 | 156       |
| 5  | Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12836.   | 2.6 | 129       |
| 6  | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. <i>World Journal of Gastroenterology</i> , 2017, 23, 4491.                                     | 3.3 | 118       |
| 7  | The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016, 34, 269-278.   | 1.9 | 105       |
| 8  | Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 7515.                | 3.3 | 102       |
| 9  | Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.         | 3.3 | 101       |
| 10 | Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. <i>Nutrients</i> , 2020, 12, 65.                         | 4.1 | 98        |
| 11 | Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 641-656. | 3.0 | 95        |
| 12 | Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , 2019, 25, 4360-4382.                      | 3.3 | 83        |
| 13 | Radial Artery as a Coronary Artery Bypass Conduit. <i>Journal of the American College of Cardiology</i> , 2016, 68, 603-610.  | 2.8 | 80        |
| 14 | Physiology and pathophysiology of liver lipid metabolism. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1055-1067.   | 3.0 | 77        |
| 15 | Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.                      | 0.9 | 77        |
| 16 | Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068.               | 3.7 | 76        |
| 17 | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , 2013, 59, 1014-1021.   | 3.7 | 75        |
| 18 | Use and indications of cholestyramine and bile acid sequestrants. <i>Internal and Emergency Medicine</i> , 2013, 8, 205-210.  | 2.0 | 75        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , 2020, 40, 878-888.   | 3.9 | 68        |
| 20 | Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. <i>Transplantation Reviews</i> , 2014, 28, 92-101.   | 2.9 | 67        |
| 21 | Gut microbiota and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2013, 8, 11-15.   | 2.0 | 66        |
| 22 | Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , 2015, 21, 12322.  | 3.3 | 65        |
| 23 | Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1301-1311.                                   | 3.7 | 63        |
| 24 | Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.   | 2.5 | 58        |
| 25 | Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.                | 0.9 | 53        |
| 26 | Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. <i>Liver International</i> , 2021, 41, 1320-1334.  | 3.9 | 51        |
| 27 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.   | 2.0 | 50        |
| 28 | Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.  | 3.2 | 47        |
| 29 | Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , 2019, 25, 4437-4451.   | 3.3 | 47        |
| 30 | What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. <i>World Journal of Gastroenterology</i> , 2012, 18, 5014.  | 3.3 | 46        |
| 31 | Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. <i>World Journal of Gastroenterology</i> , 2012, 18, 6693.  | 3.3 | 46        |
| 32 | Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689. | 3.7 | 44        |
| 33 | Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.                      | 0.9 | 41        |
| 34 | Diagnosis and treatment of small intestinal bacterial overgrowth. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 215-227.  | 3.0 | 40        |
| 35 | Sarcopenia in Patients with Advanced Liver Disease. <i>Current Protein and Peptide Science</i> , 2018, 19, 681-691.   | 1.4 | 40        |
| 36 | Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.  | 0.9 | 38        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.  | 3.3 | 37        |
| 38 | Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 370-374.         | 1.4 | 36        |
| 39 | Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , 2020, 8, 1140.   | 3.6 | 35        |
| 40 | Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms. <i>World Journal of Gastroenterology</i> , 2017, 23, 1241.  | 3.3 | 33        |
| 41 | Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.                                      | 3.9 | 28        |
| 42 | Diagnosis of bowel diseases: The role of imaging and ultrasonography. <i>World Journal of Gastroenterology</i> , 2013, 19, 2144.  | 3.3 | 25        |
| 43 | Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <i>Nutrients</i> , 2021, 13, 2649.  | 4.1 | 24        |
| 44 | Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , 2022, 28, 2251-2281.                               | 3.3 | 23        |
| 45 | Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1492-1501.   | 4.3 | 22        |
| 46 | Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.  | 0.6 | 21        |
| 47 | Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 983-991.   | 2.4 | 18        |
| 48 | Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. <i>Digestive and Liver Disease</i> , 2015, 47, 689-694.            | 0.9 | 17        |
| 49 | Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1941-1948.  | 1.8 | 17        |
| 50 | Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , 2020, 12, 3101.   | 4.1 | 17        |
| 51 | Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , 2019, 22, 157-165.   | 1.3 | 16        |
| 52 | Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature. <i>Journal of Ultrasound</i> , 2019, 22, 349-358.  | 1.3 | 15        |
| 53 | Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. <i>American Journal of Kidney Diseases</i> , 2017, 70, 297-300. | 1.9 | 14        |
| 54 | Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.   | 0.9 | 13        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.   | 3.9 | 13        |
| 56 | Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.  | 1.7 | 13        |
| 57 | Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1479-1487.   | 1.8 | 12        |
| 58 | Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 2605.                                   | 2.4 | 12        |
| 59 | Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1341-1356.                              | 2.0 | 12        |
| 60 | Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , 2012, 25, 448-454.   | 1.6 | 11        |
| 61 | Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.  | 1.3 | 10        |
| 62 | Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , 2021, 13, 62.   | 3.4 | 10        |
| 63 | Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.  | 3.7 | 9         |
| 64 | Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 347-360.   | 4.1 | 9         |
| 65 | Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. <i>European Journal of Radiology</i> , 2019, 114, 32-37. | 2.6 | 8         |
| 66 | Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021, 53, 1232-1234.                      | 0.9 | 8         |
| 67 | Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.  | 2.5 | 8         |
| 68 | The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1535-1546.   | 3.3 | 7         |
| 69 | Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.  | 1.6 | 7         |
| 70 | Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , 2019, 9, 15373.  | 3.3 | 7         |
| 71 | Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <i>PLoS ONE</i> , 2020, 15, e0235359.   | 2.5 | 7         |
| 72 | Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , 2020, 38, 522-533.  | 1.9 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. <i>Liver International</i> , 2017, 37, 1251-1251.   | 3.9 | 6         |
| 74 | Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.  | 3.1 | 6         |
| 75 | Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1493-1500. | 2.0 | 6         |
| 76 | Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. <i>Gastroenterology</i> , 2021, 160, 1891-1893.  | 1.3 | 6         |
| 77 | Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 3255.  | 3.3 | 6         |
| 78 | VIRAL CIRRHOSIS: AN OVERVIEW OF HAEMOSTATIC ALTERATIONS AND CLINICAL CONSEQUENCES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009033.  | 1.3 | 6         |
| 79 | Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients. <i>Internal and Emergency Medicine</i> , 2022, 17, 1327-1334.   | 2.0 | 6         |
| 80 | Low molecular weight heparin as cause of liver injury: case report and literature review. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 7649-7654.  | 0.7 | 6         |
| 81 | Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 183-189.  | 1.0 | 5         |
| 82 | Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. <i>Journal of Viral Hepatitis</i> , 2021, 28, 651-656.  | 2.0 | 5         |
| 83 | Advances in pharmacotherapeutics for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1343-1354.  | 1.8 | 5         |
| 84 | Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. <i>Annals of Hepatology</i> , 2012, 11, 338-42.                                      | 1.5 | 5         |
| 85 | Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2220-2222.   | 2.3 | 4         |
| 86 | Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.   | 0.9 | 3         |
| 87 | Letter: liver involvement and mortality in COVID-19 patients – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1264-1265.   | 3.7 | 3         |
| 88 | Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1005.  | 2.5 | 3         |
| 89 | Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 295-297.  | 1.5 | 2         |
| 90 | NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020, 73, 723.   | 3.7 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Reverse time-dependent effect of alfafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1322-1331. | 2.0 | 2         |
| 92  | Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Digestive and Liver Disease, 2021, 53, 541-544.   | 0.9 | 1         |
| 93  | Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. Hepatology, 2021, 74, 1718-1718.   | 7.3 | 1         |
| 94  | Diet-Induced Alterations in Gut Microbiota Composition and Function. , 2022, , .   |     | 1         |
| 95  | How to modulate gut microbiota: diet, preprobiotics or antibiotics?. Minerva Gastroenterology, 2017, 63, 411-419.  | 0.5 | 1         |
| 96  | Reply to Nezc. European Journal of Cardio-thoracic Surgery, 2016, 49, 1021.2-1022.   | 1.4 | 0         |
| 97  | Bile Collection Detected With BrIDA Scintigraphy in a Patient With Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2018, 43, 823-824.   | 1.3 | 0         |
| 98  | Letter: improvement of clinical outcomes by metformin in metabolic liver diseaseâ€”a microbiotaâ€”dependent mechanism?. Alimentary Pharmacology and Therapeutics, 2019, 50, 474-474.                               | 3.7 | 0         |
| 99  | Editorial: Before and after Liver Transplantation. The Open Transplantation Journal, 2011, 5, 30-31.   | 0.1 | 0         |
| 100 | Walking on the Molecular Pathway: m-TOR Inhibition in the Liver Transplant Setting. The Open Transplantation Journal, 2011, 5, 35-43.  | 0.1 | 0         |
| 101 | Bridge Treatments for HCC in the Waiting List for Liver Transplantation. The Open Transplantation Journal, 2011, 5, 44-49.   | 0.1 | 0         |